骨肿瘤治疗药物的研究  Ⅰ.~(153)Sm及~(153)Sm-EDTMP的制备

STUDIES ON BONE TUMOR THERAPEUTIC RADIOPHARMACEUTICALS Ⅰ. PREPARATION OF ~(163)Sm AND ~(153)Sm-EDTMP LUO SHUNZHONG PU MANFEI LI YUQIAN LIU ZHONGLIN

摘要: 作者用天然丰度的钐氧化物(Sm_2O_3,~(152)Sm丰度为26.7％)作靶料,在中子注量率为4×10~(13)n/cm~2·s的条件下,照射时间大于110h,可得核纯很高。比度不低于5.18GBq(140mCi)/mg Sm_2O_3的~(153)Sm。~(153)Sm与EDTMP(乙二胺四甲撑膦酸)络合条件的研究表明:在pH为8-10的范围内,沸水浴中反应30min,~(153)Sm-EDTMP产率大于98％。采用~(153)Sm示踪法测定了Sm(~(153)Sm)-EDTMP的组成,结果证明,Sm(~(153)Sm)与EDTMP络合组成为1:1。~(153)Sm-EDTMP稳定性实验结果表明:在络合物形成后的一个星期内,产率基本不变。
- 骨肿瘤 /
- 治疗药物 /
- ~(153)Sm /
- ~(153)Sm-EDTMP
Abstract: In this paper, 153Sm with high radionuclear purity and specific activity (5.18GBq (l40mCi) /mg Sm2O3) is prepared by irradiating natural Sm2O3 (152Sm,26.7%) sample, replacing costly enriched Sm2O3 target, at a flux of 4×1013n·cm-2·s-1 for a period up to 110h. The yield of 153Sm complexes with EDTMP is up to 99% at pH 8-10, in boiling water bath for 30min. The formation of Sm(153Sm)-EDTMP is measured by 153Sm tracer technique. The results show that the ratio of Sm(153Sm)to EDTMP is 1:1.
- Bone tumor /
- Therapeutic radiopharmaceutical /
- (153)~Sm /
- (153)~Sm-EDTMP.

[1]	Joshi, D.P. et al., JAMA, 193, 621(1965) .
[2]	Kaplan, E. et al., J.Nucl.Med., 1, 1 (1960) .
[3]	Potsaid, M.S. et al., J.Nucl.Med., 19, 98 (1978) .
[4]	Lawrence, J.H. et al., Ann.Intern.Med., 33． 41(1950) .
[5]	Silberstein, E.B. et al., J.Nucl.Med., 26, 345 (1985) .
[6]	Reddy, E.K. et al., J.Natl.Med.Assoc.,78,27 (1986) .
[7]	Eisenhut,M.et al.,J.Nucl.Med.,27, 1255 (1986) .
[8]	Goeckeler, W .F,et al., Nucl.Med.Biol., 13, 479 (1986) .